Sugi Predict

Sugi Predict / Compounds / SCHEMBL709551

SCHEMBL709551

SCHEMBL709551

COC[C@@H](C)Oc1cc(OCc2ccccc2F)cc(-c2nc3cccnc3[nH]2)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 9/20 0.38
▸ CYP1A1 P04798 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP1B1 Q16678 1/20 0.37
▸ EGFR P00533 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMO Q99835 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ RARA P10276 1/20 0.33
▸ RARB P10826 1/20 0.33
▸ RARG P13631 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709552 1.00 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL2085435 1.00 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL710297 0.89 EGFR (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL710298 0.89 EGFR (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL710274 0.88 CYP1A1 (0.45) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL2086747 0.87 PRMT5 (0.41) GCKPRMT5ACHERARARARB
SCHEMBL712325 0.87 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL708887 0.87 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL708888 0.87 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR
SCHEMBL711480 0.87 GCK (0.38) GCKCYP1A1CYP1A2CYP1B1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP claimed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US claimed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US claimed
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GCK 1/4885CYP1A1 1205/4885CYP1A2 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.